{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458638503
| type = mab
| image = 
| alt = 
| mab_type = mab
| source = u
| target = [[Death receptor 5|DR5]]
| tradename = 
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 912628-39-8
| ATC_prefix = none
| ATC_suffix = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SQ67484MA7
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| C=6334 | H=9792 | N=1700 | O=2000 | S=42
| molecular_weight = 143.1 kg/mol
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09888
}}

'''Drozitumab''' is a human monoclonal antibody in development for the treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref> It targets [[Tumour Necrosis Factor Related Apoptosis-inducing Ligand]] (TRAIL), whose receptors are found on the surface of many types of malignant cells.<ref name="Adis" /> Drozitumab was developed by [[Genentech]].

Although drozitumab was studied in [[phase II trial]]s for treating [[chondrosarcoma]], [[colorectal cancer]], [[non-Hodgkin lymphoma]], and [[non-small cell lung cancer]], development has been halted due to lack of clinical response.<ref name="Adis">{{cite web|title=Drozitumab|url=http://adisinsight.springer.com/drugs/800025104|website=AdisInsight|accessdate=31 January 2017}}</ref> 

== References ==

<references/>

{{monoclonals for tumors}}

[[Category:Monoclonal antibodies]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}